Strongest evidence outcomes:
- Increased 25-hydroxyvitamin D levels (6 studies, high evidence): All studies reported beneficial effects, with doses ranging from 240 IU/day to 50,000 IU/week. Effect sizes varied widely, and the form of vitamin D (calcifediol vs. cholecalciferol) may influence efficacy.
- Improved insulin sensitivity (6 studies, moderate evidence): 5 of 6 studies found small-to-large benefits, most consistently in vitamin D-deficient women with PCOS and diabetes/prediabetes patients. One high-quality meta-analysis in obese children found no effect.
- Reduced HOMA-IR (4 meta-analyses, moderate evidence): 3 of 4 showed small-to-moderate reductions; the neutral study noted a benefit for vitamin D2 over D3.
- Improved quality of life (4 studies, moderate evidence): All reported small benefits across clinical populations (Alzheimer's disease, chronic urticaria, cancer). One systematic review cited 4000 IU/day or 60,000 IU/week.
- Reduced C-reactive protein (4 studies, moderate evidence): 3 of 4 showed moderate reductions in CRP in obesity/diabetes populations, though many studies used co-supplementation.
Mixed or weaker evidence outcomes:
For outcomes such as reduced inflammation (4 studies, small effects, low evidence), blood cholesterol (mostly neutral, low evidence), BMI (3 of 4 neutral, low evidence), triglycerides (2 beneficial, 2 neutral, low evidence), LDL cholesterol (mostly neutral, low evidence), fasting blood glucose (mostly neutral, low evidence), and interleukin-6 (2 of 3 beneficial, low evidence), the findings are preliminary and inconsistent. In these areas, effects are generally small, many studies did not reach statistical significance, and results may be limited to specific clinical subgroups.
Effective dose patterns:
There is no single consistent effective dose across outcomes. Studies used doses from 200 IU/day (in one IL-6 study) up to 50,000 IU/week, with a median duration around 90 days. For blood-level elevation, doses from 4000 IU/day to 60,000 IU/week were reported. Many syntheses lacked consistent dose reporting, making precise dose-response conclusions difficult.
Population insights:
Benefits were most consistently seen in individuals with vitamin D deficiency or specific clinical conditions: women with PCOS, patients with diabetes/prediabetes, metabolic-associated fatty liver disease, and autoimmune or inflammatory conditions (e.g., rheumatoid arthritis, psoriatic arthritis, multiple sclerosis). General or pediatric populations with obesity more often showed neutral results.
Notable caveats:
- Publication bias is a recurring concern across many syntheses — null results may be underrepresented.
- Some beneficial studies used co-supplementation with other nutrients (magnesium, probiotics, omega-3s, vitamin E), making it difficult to isolate the effect of vitamin D alone.
- Many studies did not report the form of vitamin D (D2 vs. D3) or specific doses, limiting practical interpretation.
- Evidence strength is limited by small numbers of studies (many syntheses include only 3-4 papers) and inconsistent effect sizes.